These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Drug development for neglected diseases: a deficient market and a public-health policy failure. Trouiller P; Olliaro P; Torreele E; Orbinski J; Laing R; Ford N Lancet; 2002 Jun; 359(9324):2188-94. PubMed ID: 12090998 [TBL] [Abstract][Full Text] [Related]
23. [Development of new drugs is too expensive]. Andreasen J Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066 [No Abstract] [Full Text] [Related]
24. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs]. Giri I; Rouillon F Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487 [No Abstract] [Full Text] [Related]
25. Probing the link between gross profitability and R&D spending. Lichtenberg FR Health Aff (Millwood); 2001; 20(5):221-2. PubMed ID: 11558707 [No Abstract] [Full Text] [Related]
27. Rising research and development costs for new drugs in a cost containment environment. DiMasi JA Pharmacoeconomics; 1992; 1(Suppl 1):13-20. PubMed ID: 10146926 [TBL] [Abstract][Full Text] [Related]
28. Measuring US pharmaceutical industry R&D spending. Golec J; Vernon J Pharmacoeconomics; 2008; 26(12):1005-17. PubMed ID: 19014202 [TBL] [Abstract][Full Text] [Related]
29. The link between gross profitability and pharmaceutical R&D spending. Scherer FM Health Aff (Millwood); 2001; 20(5):216-20. PubMed ID: 11558706 [No Abstract] [Full Text] [Related]
30. Drugs in pregnancy: acknowledging challenges--finding solutions. Koren G; MacLeod S; Davis D Can J Clin Pharmacol; 2007; 14(1):e2-4. PubMed ID: 17213506 [No Abstract] [Full Text] [Related]
31. A changing drug supply. Nature; 2007 Feb; 445(7127):460. PubMed ID: 17268432 [No Abstract] [Full Text] [Related]
32. Drug development for maternal health cannot be left to the whims of the market. PLoS Medicine Editors PLoS Med; 2008 Jun; 5(6):e140. PubMed ID: 18578567 [TBL] [Abstract][Full Text] [Related]
33. The extinction of drugs for clinical research: Can the ECNP medicines chest save them? Nutt D; Kilpatrick G; Hayes A Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534 [No Abstract] [Full Text] [Related]
34. Recombinant protein therapeutics--success rates, market trends and values to 2010. Pavlou AK; Reichert JM Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654 [No Abstract] [Full Text] [Related]
35. Drugs of choice in pregnancy: primary prevention of birth defects. Peters PW; Garbis-Berkvens HM; Bannigan JG Reprod Toxicol; 1993; 7(5):399-404. PubMed ID: 8274815 [No Abstract] [Full Text] [Related]
36. [The financing and price regulation of drugs in the Spanish National Health System: changes and continuity]. Puig-Junoy J Gac Sanit; 2007; 21(1):1-4. PubMed ID: 17306178 [No Abstract] [Full Text] [Related]
37. Drugs in pregnancy and their effects on pre- and postnatal development. Kelsey FO Res Publ Assoc Res Nerv Ment Dis; 1973; 51():233-43. PubMed ID: 4590403 [No Abstract] [Full Text] [Related]
38. Drugs in pregnancy. Koren G; Pastuszak A; Ito S N Engl J Med; 1998 Apr; 338(16):1128-37. PubMed ID: 9545362 [No Abstract] [Full Text] [Related]
39. Rising costs hold up drug discovery. Miller HI Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407 [No Abstract] [Full Text] [Related]